Xeroderma pigmentosa with ocular association: Case report


Xeroderma pigmentosum is a rare, autosomal recessive disease caused by a defect in DNA repair. Patients with xeroderma pigmentosum often have cutaneous and ocular sun sensitivity, freckle-like skin pigmentation, multiple skin and eye cancers, and, in some patients, progressive neurodegeneration. Xeroderma pigmentosum predominantly affects the ultraviolet (UV) exposed ocular surface, resulting in eyelid atrophy and cancers, corneal dryness, exposure keratopathy, and conjunctival tumors. General features included parental consanguinity (40%), familiarity (60%), onset of symptoms in the first 2 years (50%), malignant skin neoplasms (60%), and carcinoma of the tongue (20%). Among the ocular features, 50% of patients presented with photophobia. Lid freckles or atrophic skin lesions were seen in all patients. Lower lid tumours were seen in 30%, chronic conjunctival congestion in 40%, corneal opacification in 40%, squamous cell carcinoma of limbus in 20%, bilateral pterygium in 40%, and visual impairment in 50%. We report the clinical history and ocular pathology of a boy who is having xeroderma pigmentosum with ocular manifestations. The ophthalmic manifestations of xeroderma pigmentosum are discussed and reviewed with respect to this report and other cases in the literature. These cases illustrate the role of DNA repair in protection of the eyes from UV damage and neuron degeneration of the retina.

Share and Cite:

Pandey, A. , Kuldeep, K. , Koul, A. , Tyagi, M. , Singh, P. , Sharma, P. and Dimri, D. (2013) Xeroderma pigmentosa with ocular association: Case report. Case Reports in Clinical Medicine, 2, 466-469. doi: 10.4236/crcm.2013.28123.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Hebra, F. and Kaposi, M. (1874) On diseases of the skin including exanthemata. New Sydenham Society, 61, 252-258.
[2] Cleaver, J.E. (1968) Defective repair replication of DNA in xeroderma pigmentosum. Nature, 218, 652-656.
[3] Kraemer, K.H. (2008) In: Pagon, R.A., Bird, T.C., Dolan, C.R. and Stephens, K., Eds., Xeroderma Pigmentosum, University of Washington, Seattle.
[4] Kleijer, W.J., Laugel, V. and Berneburg, M., et al. (2008) Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair (Amst), 7, 744-750.
[5] Hirai, Y., Kodama, Y., Moriwaki, S., et al. (2006) Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. Mutation Research, 601, 171-178.
[6] Reese, A.B. and Wilber, I.E. (1943) The eye manifestations of xeroderma pigmentosum. American Journal of Ophthalmology, 26, 901-911.
[7] O’Malley, P.F. and Allen, R.A. (1967) Peripheral cystoid degeneration of the retina. Incidence and distribution in 1000 autopsy eyes. Archives of Ophthalmology, 77, 769-776.
[8] Pearce, W.G. (1972) Ocular and genetic features of Cockayne’s syndrome. Canadian Journal of Ophthalmology, 7, 435-444.
[9] Dollfus, H., Porto, F., Caussade, P., et al. (2003) Ocular manifestations in the inherited DNA repair disorders. Survey of Ophthalmology, 48, 107-122.
[10] Brumback, R.A., Yoder, F.W., Andrews, A.D., et al. (1978) Normal pressure hydrocephalus. Recognition and relationship to neurological abnormalities in Cockayne’s syndrome. Archives of Neurology, 35, 337-345.
[11] Broughton, B.C., Cordonnier, A., Kleijer, W.J., et al. (2002) Molecular analysis of mutations in DNA polymerase ETA in xeroderma pigmentosum-variant patients. Proceedings of the National Academy of Sciences of the United States of America, 99, 815-820.
[12] Robbins, J.H., Kraemer, K.H., Merchant, S.N. and Brumback, R.A. (2002) Adult-onset xeroderma pigmentosum neurological disease—Observations in an autopsy case. Clinical Neuropathology, 21, 18-23.
[13] Chidzonga, M.M., Mahomva, L., Makunike-Mutasa, R. and Masanganise, R. (2009) Xeroderma pigmentosum: A retrospective case series in Zimbabwe. Journal of Oral and Maxillofacial Surgery, 67, 22-31.
[14] El Hefnawi, H., Rasheed, A. and Xeroderma, P. (1966) A report of further six cases. The Journal of the Egyptian Medical Association, 49, 419-434.
[15] Blanksma, L.J., Donders, P.C. and van Voorst, V.P.C. (1986) Xeroderma pigmentosum and keratoconus. Documenta Ophthalmologica, 64, 97-103.
[16] Johnson, M.W., Skuta, G.L., Kincaid, M.C., et al. (1989) Malignant melanoma of the iris in xeroderma pigmentosum. Archives of Ophthalmology, 107, 402-407.
[17] Kitagawa, K.O.T. and Inoue, M. (1981) Choroidal malignant melanoma occurring in a patient with xeroderma pigmentosum. Folia Ophthalmol Jpn, 32, 657-663.
[18] Kraemer, K.H., DiGiovanna, J.J., Moshell, A.N., et al. (1988) Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. The New England Journal of Medicine, 318, 1633-1637.
[19] Cook, Jr., B.E., and Bartley, G.B. (2001) Treatment options and future prospects for the management of eyelid malignancies: An evidence-based update. Ophthalmology, 108, 2088-2098.
[20] Kearsley, J.H., Fitchew, R.S. and Taylor, R.G. (1988) Adjunctive radiotherapy with strontium-90 in the treatment of conjunctival squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics, 14, 435-443.
[21] Shields, C.L. and Shields, J.A. (2004) Tumors of the conjunctiva and cornea. Survey of Ophthalmology, 49, 3-24.
[22] Shields J. (2008) Melanocytic tumors of the iris stroma: Intraocular tumors: Atlas and textbook. 2nd Edition, Chapter 2, Lippincott Williams & Wilkins, Philadelphia, 22.
[23] Limawararut, V., Leibovitch, I., Sullivan, T. and Selva, D. (2007) Periocular squamous cell carcinoma. Clinical & Experimental Ophthalmology, 35, 174-185.
[24] DiGiovanna, J.J., Patronas, N., Katz, D., et al. (1998) Xeroderma pigmentosum: Spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy. Journal of Cutaneous Medicine and Surgery, 2, 153-158.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.